Skip to content

Drug interactions

Enzalutamide + Selpercatinib

Severity: Major

Enzalutamide and Selpercatinib: major interaction.

Last updated Sources: UK SmPC

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Selpercatinib is a CYP3A4 substrate and strong inducers can substantially reduce its exposure. Enzalutamide may reduce antitumor activity.

What this interaction means in plain words

Enzalutamide and Selpercatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Enzalutamide belongs to Endocrine; Selpercatinib belongs to Oncology.

Evidence level: Moderate

Why it happens

Enzalutamide induces CYP3A4, increasing selpercatinib clearance.

What to do

Avoid concomitant strong or moderate CYP3A inducers. Consider an alternative to enzalutamide and monitor tumor response if combined.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Enzalutamide and Selpercatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

References

Frequently asked questions

Can I take Enzalutamide with Selpercatinib?

MediHelp rates the interaction as major. Enzalutamide and Selpercatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Selpercatinib is a CYP3A4 substrate and strong inducers can substantially reduce its exposure. Enzalutamide may reduce antitumor activity.

How serious is the interaction between Enzalutamide and Selpercatinib?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concomitant strong or moderate CYP3A inducers. Consider an alternative to enzalutamide and monitor tumor response if combined.

What other medicines interact with Enzalutamide?

MediHelp also lists interactions of Enzalutamide with, for example, Doravirine, Elbasvir / grazoprevir, Ensitrelvir. The full list is on the Enzalutamide page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in